-
Mashup Score: 1
Tislelizumab plus chemotherapy as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma provided superior overall survival with a manageable safety profile versus placebo plus chemotherapy. Given that the interim analysis met its superiority boundary for the primary endpoint, as confirmed by the independent data monitoring committee, this Article represents the…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Advanced oesophageal squamous cell carcinoma remains an important therapeutic challenge due to the paucity of established treatment options1 and high prevalence of comorbidities. Cytotoxic chemotherapy has been the main treatment option for systemic spread because it can delay disease progression and prolong life in selected patients.2,3 Other treatments, such as radiotherapy, are also…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"The results of RATIONALE-306 support the use of immune checkpoint inhibitors with chemotherapy in first-line treatment of advanced oesophageal squamous cell carcinoma." Linked Comment by Katrin Marie Sjoquist. https://t.co/Ja27fToEsS
-
-
Mashup Score: 1
Adjuvant carboplatin and paclitaxel chemotherapy given after standard cisplatin-based chemoradiotherapy for unselected locally advanced cervical cancer increased short-term toxicity and did not improve overall survival; therefore, it should not be given in this setting.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NOW OF: In the OUTBACK ph 3 trial of adjuvant chemotherapy after chemoradiotherapy for locally advanced cervical cancer, 5-year OS was 72% (95% CI 67-76) w/ adjuvant chemotherapy group and 71% (66=75) w/o (HR 0·90, 95% CI 0·70-1·17; p=0·81). #gyncsm https://t.co/jDy5S9fz0Z https://t.co/gd1ZNSpESJ
-
-
Mashup Score: 0Sweeping new US EPA air pollution rules - 2 year(s) ago
The US Environmental Protection Agency (EPA) announced a series of sweeping new restrictions on toxic air pollution, with proposed rules that would reduce carcinogenic and other dangerous exposures in low-income neighbourhoods and communities of colour while also reducing the country’s contributions to climate change.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEWS: Sweeping new US EPA air pollution rules https://t.co/huAZzELZKT
-
-
Mashup Score: 0UK Government “swap to stop” plan to cut smoking rates - 2 year(s) ago
1 million smokers in England will be offered a free vape starter kit alongside behavioural support, the UK Government has announced.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEWS: UK Government “swap to stop” plan to cut smoking rates https://t.co/XbgkftkER3
-
-
Mashup Score: 0US Government releases National Cancer Plan - 2 year(s) ago
On April 3, 2023 the US National Cancer Institute released its long-anticipated National Cancer Plan, a roadmap and call to action to improve all facets of cancer care from prevention, screening, and early detection through to treatment and survivorship care.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEWS: US Government releases National Cancer Plan https://t.co/dTwqLX4nOy
-
-
Mashup Score: 1
This first-in-patient study showed that OTL78 was well tolerated and had the potential to improve prostate cancer detection. Optimal dosing was 0·03 mg/kg, 24 h preoperatively. PSMA-directed fluorescence imaging allowed real-time identification of visually occult prostate cancer and might help to achieve complete oncological resections.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NOW OF: In a single-arm, phase 2a, feasibility trial, PSMA-targeted fluorescent tracer OTL78 was well tolerated and had the potential to improve prostate cancer detection in patients with prostate cancer. #pcsm https://t.co/VN9wYE8pyr https://t.co/q1nhVazAqd
-
-
Mashup Score: 0From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit - 2 year(s) ago
The departure of the UK from the European Union (EU) and affiliated European regulatory bodies, including the European Medicines Agency, on Dec 31, 2020, has resulted in the Medicines and Healthcare products Regulatory Agency becoming an independent national regulator. This change has required a fundamental transformation of the UK drug regulatory landscape, creating both opportunities and…
Source: The Lancet OncologyCategories: Latest Headlines, Oncologists2Tweet-
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit https://t.co/QNCbK41vTS
-
-
Mashup Score: 1From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit - 2 year(s) ago
The departure of the UK from the European Union (EU) and affiliated European regulatory bodies, including the European Medicines Agency, on Dec 31, 2020, has resulted in the Medicines and Healthcare products Regulatory Agency becoming an independent national regulator. This change has required a fundamental transformation of the UK drug regulatory landscape, creating both opportunities and…
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
2/n ... From @EMA_News to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following #Brexit https://t.co/SykjlIP3XD via @DrMarkLythgoe et al
-
-
Mashup Score: 2Endocrine disruptors—the lessons (not) learned - 2 year(s) ago
The recent case of a sunscreen company, Coppertone, recalling five of its products because they contained benzene, an endocrine disruptor, has rekindled the debate around use of these substances. WHO classifies endocrine disruptors as exogenous substances that can potentially alter the endocrine system. These substances can be found in everday products, such as foods and cosmetics, as well as…
Source: The Lancet OncologyCategories: Future of Medicine, Latest HeadlinesTweet-
RT @NeilFlochMD: Endocrine disruptors—the lessons (not) learned - The Lancet Oncology https://t.co/uXRBmPm1nO
-
NOW OF: Interim analysis of the RATIONALE-306 trial of 1st-line tislelizumab + chemo vs placebo + chemo in adv or metastatic oesophageal squamous cell carcinoma—median OS 17·2 mo (95% CI 15·8–20·1) vs 10·6 mo (9·3–12·1; HR 0·66, 95% CI 0·54–0·80; p<0·0001) https://t.co/25lyg2Ef0o https://t.co/vizCPVd8bj